This is an open-label, comprehensive, iterative investigation of evaluating the use of induction chemotherapy, high-dose chemotherapy, and focal radiation therapy in children with newly diagnosed Embryonal Tumor With Multilayered Rosettes (ETMR).PRIMARY OBJECTIVES I. To determine the six-month progression-free survival (PFS6) of participants with newly diagnosed, gross-totally resected, non-metastatic ETMR, treated using a regimen of induction chemotherapy and early focal radiotherapy (Cohort 1)SECONDARY OBJECTIVES I. To determine the two-year progression-free survival (PFS) and overall survival (OS) of participants with newly diagnosed, gross-totally resected, non-metastatic ETMR (Cohort 1).THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

Kids and teens with asthma often get less physical activity than recommended, even though exercise can improve asthma symptoms, lung function, overall fitness, and mental health. But we don’t fully understand: • How active our own clinic’s patients actually are • What they think about exercise • What gets in the way • What kinds of at home exercise options they might be interested in This study aims to fill those gaps so the clinic can better support families in building healthy activity habits.THIS STUDY IS ENROLLING BY INVITATION ONLY - Participants will be approached during a regularly scheduled pulmonology clinic visit and, if interested, will participate in the consent/assent discussion.

The DNA repair capacity (DRC) is a measure of a cell’s ability to repair DNA damage. High levels of DNA damage are observed in many lung diseases, including lung cancer and chronic obstructive lung disease (COPD, sometimes referred to as emphysema or chronic bronchitis). We believe that patients with a lower DRC may be at higher risk for development of lung diseases including lung cancer and COPD. The purpose of this study is to measure the DRC in peripheral blood monocytes from smoking and non-smoking patients with and without lung cancer compared to healthy controlsTHIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

What is the purpose of this study?The main objective of this study is to determine if Home OCT-guided treatment results in 1) better visual acuity outcomes and/or 2) fewer number of injections over 104 weeks compared with treat and extend (T&E) dosing for nAMD. 

Bronchiectasis is a chronic respiratory disease characterized by irreversible airway damage and recurrent infection, and many patients remain without an identifiable cause even after standard testing. Primary ciliary dyskinesia (PCD), a genetic disorder that causes bronchiectasis due to defecttive mucus clearance in the lungs, is substantially underdiagnosed in adult bronchiectasis patients based on recent genetic sutdies. Identifying unrecognized PCD in adult bronchiectasis patients is essential because it would enable more precise clinical management, guide genetic counseling, and ensure timely access to future therapies, all of which motivate the need for this study.THIS STUDY IS ENROLLING BY INVITATION ONLY - All subjects who will be approached for participation in this trial will be patients from the practice of one of the investigators (Dr. Cynthia Brown) or another physician in the Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine. This will include patients seen at both Indiana University Health Facilities, as well as Eskenazi Health. A patient will only be approached for study participation after the physician who has a treatment relationship with the patient (which may or may not be the PI) has given permission. Recruitment will occur during scheduled outpatient visits in the IU Health Adult Pulmonology clinics, where potentially eligible patients are approached only after their treating clinician has identified them as appropriate for contact.